EMA Authorised: Flebogamma DIF (previously Flebogammadif) (human normal immunoglobulin) — Instituto Grifols S.A.

View source ↗

Summary

EMA authorises Flebogamma DIF (human normal immunoglobulin) for multiple immunological indications including mucocutaneous lymph node syndrome, Guillain-Barre s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Marrow Transplantation
• Guillain-barré Syndrome
• Immunologic Deficiency Syndromes
• Mucocutaneous Lymph Node Syndrome
• Purpura Thrombocytopenic Idiopathic

Drugs mentioned

• Flebogamma DIF (human normal immunoglobulin)

Snippet

Status: Authorised. Therapeutic area: Mucocutaneous Lymph Node Syndrome;Guillain-Barre Syndrome;Bone Marrow Transplantation;Purpura, Thrombocytopenic, Idiopathic;Immunologic Deficiency Syndromes. MAH: Instituto Grifols S.A.. Decision date: 30/10/2023